Subscribe Sign in

Business

Codan vs Pro Medicus: Which ASX growth stock is better value?

1 min read Rewritten in plain language

Growth SharesAssisted

Show what we removed Rules applied: A1×5 A3×7 A4 A6×2 A9×4 D1 D2 D3×15 E3×5 E5 F2×2 all 30 rules
  • Let's break down what sets Codan and Pro Medicus apart when it comes to value, growth, and recent momentum.
  • Through segments like Codan Communications, Minelab, Minetec, and Defence Electronics, the company serves government, military, and commercial customers in dozens of countries.
  • What stands out for Codan right now is just how quickly it's compounded shareholder value.
  • The market cap, at $17.68 billion, puts Pro Medicus in a different league to Codan.
  • Its shares fell from $198.85 on 19 August 2026 to $169.22 on 17 September 2026 — a drop of about 15%.

5 sentences from our version of the report, chosen to cover it. Nothing here is written; every line is in the article below. How

Headline check

All two things this headline claims are in the report.

Figures, names and quoted words in the headline, looked for in the report itself — not in the summary above. How this is checked

Let's break down what sets Codan and Pro Medicus apart when it comes to value, growth, and recent momentum.

Codan is a global technology player, best known for high-tech communications, metal detection, and mining solutions. Through segments like Codan Communications, Minelab, Minetec, and Defence Electronics, the company serves government, military, and commercial customers in dozens of countries. According to its company profile, Codan controls its own products end-to-end, with manufacturing plants in Australia and Malaysia, and a sales footprint concentrated in North America.

What stands out for Codan right now is just how quickly it's compounded shareholder value. The company's P/E ratio is on the higher side at 51.03, suggesting it's priced as a growth stock with high expectations. A dividend yield of 0.99% won't turn heads for income buffs, but it's at least ahead of most tech or high-growth names.

Pro Medicus sits at the cutting edge of digital healthcare, supplying advanced radiology and medical imaging systems across the globe. As per its most recent public description, most Pro Medicus's success story has played out in the US, where many hospitals have adopted its technology.

The market cap, at $17.68 billion, puts Pro Medicus in a different league to Codan.

Codan's share price moved from $43.48 on 19 August 2026 up to $48.59 on 17 September 2026, a gain of around 12%.

Its shares fell from $198.85 on 19 August 2026 to $169.22 on 17 September 2026 — a drop of about 15%.

Shortened to 1 minute of reading, this version reads 12.8 on the Niral Score.

You are reading our version, not theirs. This is The Motley Fool Australia's report shortened to its most important sentences, in plainer words, with verdicts and loaded words taken out. Plain description stays, and so do adjectives that carry a fact, such as "former" or "federal". The reporting, the facts and the quotations are theirs — quotations are never edited — and the indicators beside it measure this version. Hover or tap Adjectives to see every one left in the text.

How this outlet filed it, and how we rewrote it

No other newsroom we read has filed on this event, so there is nothing to compare it with yet.

Outlet Niral ScoreAdjectivesSourcingSentimentHappiness
The Motley Fool Australiaas they published this story 23.8 37 3 0.2 59.2
Mundane Readneutralized from The Motley Fool Australia 17.2 32 3 0.2 59.2

Sign in to react.

Comments

Nothing here yet.

Sign in to comment.

Questions

Readers can ask a question about this story here. Questions and answers are for subscribers. Sign in to read them.

Comments are read before they appear where anything in them needs a person to look. Nothing posted here is ever deleted; a comment taken down keeps its text and the reason, so the decision can be looked at again. How this works